Table 1.
Overview of the cited studies regarding the ablational procedures on iCCA.
| Procedures | Authors | Design | Endpoints * | Outcome |
|---|---|---|---|---|
| RFA/MWA | ||||
| RFA | Fu et al. (2012) [23] | Monocentric; Retrospective; n = 17 |
Tumor necrosis | 96.2% |
| OS (median) | 33 months | |||
| RFS (median) | 17 months | |||
| 1Y-, 3Y-, 5Y-OS | 84.5%; 43.3%; 28.9% | |||
| RFA | Han et al. (2015) [28] | Meta-Analyses; Systematic Review; n = 84 |
1Y-, 3Y-, 5Y-OS | 82%; 47%; 24% (pooled) |
| Major complications | 2.3% | |||
| RFA/MWA | Kim et al. (2022) [29] | Meta-Analyses; Systematic Review; n = 917 |
Technical efficacy | 91.9% |
| 1Y-, 3Y-, 5Y-OS | 82.4%; 41.1%; 28.5% | |||
| 1Y-, 3Y-RFS | 40%; 19.2% | |||
| 1Y-, 3Y-, 5Y-TTLTP | 79.3%; 59.5%; 58.2% | |||
| Major complications | 5.7% | |||
| MWA | Zhang at al. (2018) [36] | Monocentric; Retrospective; n = 107 |
OS (median) | 28.0 months |
| 1Y-, 3Y-, 5Y-OS | 93.5%; 39.6%; 7.9% | |||
| 6 m-, 12 m-, 18 m-, 24 m-PFS | 67.4%; 41.5%; 18.2%; 8.7% | |||
| Major complications | 2.8% | |||
| MWA vs. SR | Xu et al. (2019) [37] | Monocentric; Retrospective; n = 121 |
MWA: | |
| 5Y-OS (estimated) | 23.7% | |||
| 3Y-RFS (estimated) | 33.1% | |||
| Major complications | 5.3% (sign.) | |||
| Surgical resection: | ||||
| 5Y-OS (estimated) | 21.8% | |||
| 3Y-RFS (estimated) | 30.6% | |||
| Major Complications | 13.8% (sign.) | |||
| MWA + TACE | Yang et al. (2015) [38] | Monocentric; Retrospective; n = 26 |
OS (median) | 19.2 months |
| PFS (median) | 6.2 months | |||
| 6 m-, 12 m-, 24 m-OS | 88.5%; 69.2%; 61.5% | |||
| Major complications | 0% | |||
| Cryoablation | ||||
| Currently no significant evidence available | ||||
| CT-HDRBT | ||||
| CT-HDRBT | Schnaauff et al. (2012) [50] | Monocentric; Retrospective; n = 15 |
OS (median) | 14 months |
| LTC (median) | 11 months | |||
| CT-HDRBT | Kamphues et al. (2012) [51] | Monocentric; Retrospective; n = 10 |
1Y-, 5Y-OS | 77.1%; 51.4% |
| Major complications | 0% | |||
| CT-HDRBT | Jonczyk et al. (2018) [52] | Monocentric; Retrospective; n = 61 |
iCCA < 4 cm: | |
| OS (median) | 15.5 months | |||
| LTC (median) | 8.0 months (sign.) | |||
| PFS (median) | 5.0 months | |||
| iCCA > 4 cm: | ||||
| OS (median) | 10.0 months | |||
| LTC (median) | 6.0 months (sign.) | |||
| PFS (median) | 3.0 months | |||
| IRE | ||||
| Currently no significant evidence available | ||||
* Survival times from interventional procedures out were selected in each case.